Gynecology

September 17, 2021

As the COVID-19 pandemic prevails, many clinicians and patients question whether telemedicine will be the new mainstream form of health care.

September 15, 2021

Though limited data exist, Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

September 07, 2021

A Swedish cohort study in the journal Environment International has found that women of fertile age who were exposed to high levels of perfluorinated substances (PFAS) in drinking water were significantly more likely to subsequently have a diagnosis of polycystic ovarian syndrome (PCOS) and possibly uterine leiomyoma (or uterine fibroids [UFs]), but not endometriosis.

September 03, 2021

For full-term, low-risk, nulliparous patients, induction of labor with a Foley balloon alone or concurrent with prostaglandins (PGE) is associated with a significantly lower risk of adverse neonatal outcomes than with PGE alone, according to a study in the American Journal of Perinatology.

September 02, 2021

The U.S. Food and Drug Administration (FDA) has issued 501(k) clearance for Visby Medical’s Sexual Health Click Test, a single-use, instrument-free polymerase chain reaction (PCR) diagnostic test for sexually transmitted infections (STI).

August 20, 2021

Several dietary supplements and nutrients potentially provide benefits in preventing and treating common gynecological diseases like uterine fibroids (UFs), endometriosis, polycystic ovarian syndrome (PCOS), infertility, menstrual disorders and vaginal infections, according to an article in the journal Nutrients.

August 11, 2021

The results, according to the study authors, demonstrate that screening the general population for tubal and ovarian cancer each year does not result in a survival benefit.

August 06, 2021

The American College of Obstetricians and Gynecologists (ACOG) recently published an updated committee opinion regarding morcellation of presumed uterine leiomyoma. Here are the key points.

July 15, 2021

On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the FDA for vulvovaginal candidiasis (VVC) in adult women and girls of reproductive age.

June 11, 2021

This list was compiled by Christine R. Isaacs, MD; and William M. Leininger, MD, as a supplement to their presentation from the 2021 American College for Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), held virtually April 30-May 2.